Symetis is the leading European developer of innovative, minimally invasive heart valve replacement devices.
The company’s products, ACURATE TA™ and ACURATE neo™ and their delivery systems are based on proprietary design and delivery technologies. These products are marketed and sold across the globe and are well positioned to target the constantly growing TAVI market.
Stage Capital invested in Symetis in October 2010 as part of a $25m Series C round alongside investors including Wellington Partners, Truffle Capital, Banexi Ventures and Vinci Capital.
Symetis was acquired by Boston Scientific in March 2017 for $435 million.
Venture-stage investment in medical technology
STAGE CAPITAL TEAM